HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics
about
Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approachesCandidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesHIV related high risk behaviors and willingness to participate in HIV vaccine trials among China MSM by computer assisted self-interviewing survey.Differences in HIV vaccine acceptability between genders.Endorsement of compulsory HIV vaccination policy among populations at high risk of HIV exposure (LA VOICES).Willingness to participate in HIV vaccine trials: the impact of trial attributes.HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approachDepression treatment preferences of older white and Mexican origin menWillingness to pay for contagious bovine pleuropneumonia vaccination in Narok South District of Kenya.HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study.An extended model of reasoned action to understand the influence of individual- and network-level factors on African Americans' participation in HIV vaccine research.The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.Future HIV vaccine acceptability among young adults in South Africa.Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICESAcceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations.Socioecological influences on community involvement in HIV vaccine researchWillingness to receive an HIV vaccine among incarcerated personsAnticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women.Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences.Perceptions of sexual risk compensation following posttrial HIV vaccine uptake among young South Africans.What can HIV vaccine trials teach us about future HIV vaccine dissemination?Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).Economic Evaluations of Public Health Surveillance Systems: a Systematic Review.Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men.Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities.Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback.A small dose of HIV? HIV vaccine mental models and risk communication.High prevalence of HIV infection among rural tea plantation residents in Kericho, Kenya.HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada.'Why would you promote something that is less percent safer than a condom?': Perspectives on partially effective HIV prevention technologies among key populations in South Africa
P2860
Q25255907-B13B9365-E11A-4B65-98BE-1228152858ADQ27005602-9A9863B6-79A2-478A-9C4B-94D5AEE276B9Q30226978-6E4BC16F-19A9-4842-A6B4-A43B938F8F8AQ30357307-696FA6ED-CD96-4E69-8509-66BFDE291DC3Q30369465-6D00389F-C190-4021-B12D-5A3861B7BC50Q33638974-48A9E40F-EF08-4393-B6A3-6483F9FEA040Q33643631-ACA7DE44-EC4A-4858-9E98-AED9E1507548Q33689222-92430C6E-C9FB-447E-9E95-EA1CC8BF7FC3Q33699263-034E0D8A-53B8-4B91-BA94-BF1DAD2FF5A4Q33775686-C93F3F1D-406D-49BC-A40F-E0EE40F4A674Q33786360-7C1608A6-F32B-4BE0-B2AD-C46859528602Q33807022-83358A2F-8B51-48D3-8CE1-437AC73F245EQ33828458-42F00793-7CEA-4D44-AB9D-3373F852D3DDQ33835788-1F391927-2ED5-47A8-AF57-93DF6026D86EQ34063486-687C9DFF-865D-477A-ADAE-C0A98335BC57Q34989216-297CF04D-E63A-45F8-869F-A1FDF151ABE4Q35207849-C002CFDD-BD86-4393-A614-35F109AA6F18Q35644871-A59A6C98-731A-464C-8EA0-F35D0FCD0064Q35890620-790E6AAB-124E-4169-9040-A0EFC6DA7243Q36022717-CBADB787-7FAC-4E39-B489-9997D2843FD2Q37075094-55515C8D-068B-431C-B74C-21DD44E26DBFQ37274924-1547D0FD-E9D0-415C-BF69-286841B3C162Q37485276-7DC5B9A5-539A-45ED-9BC2-6A5DF77C9F36Q38724635-F351CA5E-B798-446B-B173-75644B27E35BQ38942170-B8245726-AE49-49F9-B3E8-2D4F7C06377AQ40001039-18039B23-5506-44C3-9F41-B16E2DAF8D0CQ40123390-D8572D40-9BFF-4E40-90F7-7DFA6319F075Q40151338-72B2084A-2E9A-47B1-9FD5-35C53BE03673Q40199592-A48C9546-E1E8-4398-8FB4-04BE1F89BD7FQ48149128-00AF065B-ED54-4CD7-908F-2602F2EA6450Q58452343-9DA31468-A628-4713-824A-8FB3F0211F9D
P2860
HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
HIV vaccine acceptability amon ...... act of vaccine characteristics
@ast
HIV vaccine acceptability amon ...... act of vaccine characteristics
@en
type
label
HIV vaccine acceptability amon ...... act of vaccine characteristics
@ast
HIV vaccine acceptability amon ...... act of vaccine characteristics
@en
prefLabel
HIV vaccine acceptability amon ...... act of vaccine characteristics
@ast
HIV vaccine acceptability amon ...... act of vaccine characteristics
@en
P2093
P2860
P1433
P1476
HIV vaccine acceptability amon ...... act of vaccine characteristics
@en
P2093
Danielle S Seiden
Ellen T Rudy
Lisa Kakinami
Naihua Duan
Sung-Jae Lee
William E Cunningham
P2860
P304
P356
10.1016/J.VACCINE.2005.11.013
P407
P577
2005-11-21T00:00:00Z